Cardiac Fibrosis: Mechanistic Discoveries Linked to SGLT2 Inhibitors

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Sodium-glucose cotransporter 2 inhibitors (SGLT2is), or flozins, are known for glucose lowering in type 2 diabetes mellitus (T2DM).
• Emerging evidence highlights their significant cardioprotective effects, independent of glycemic control.

Purpose of the Study:

• To review the anti-fibrotic mechanisms of SGLT2is in the context of heart failure.
• To correlate findings from preclinical models with human clinical trial data.

Main Methods:

• Review of key clinical trials investigating SGLT2is (empagliflozin, dapagliflozin) in heart failure.
• Analysis of preclinical animal models examining SGLT2i effects on cardiac fibrosis.
• Investigation of molecular pathways, including AMPK activation and oxidative stress.

Main Results:

• SGLT2is significantly reduce heart failure hospitalizations, cardiovascular death, and fibrosis markers.
• Preclinical studies show SGLT2is reduce cardiac fibrosis via AMPK activation, reduced oxidative stress, and inhibition of pro-fibrotic pathways.
• Cardioprotection is attributed to direct cardiac actions, immune modulation, and metabolic improvements.

Conclusions:

• SGLT2is demonstrate efficacy in treating heart failure, with anti-fibrotic effects mediated by multiple molecular targets.
• Findings support the use of SGLT2is for heart failure management.
• Further clinical trials targeting shared pathways are warranted.